Pegvaliase: Difference between revisions
Appearance
Content deleted Content added
Anypodetos (talk | contribs) No ATC code; stub template |
Anypodetos (talk | contribs) New ATC code; navbox; stub sorting |
||
Line 41: | Line 41: | ||
| class = |
| class = |
||
| ATCvet = |
| ATCvet = |
||
| ATC_prefix = |
| ATC_prefix = A16 |
||
| ATC_suffix = |
| ATC_suffix = AB19 |
||
| PubChem = 86278362 |
| PubChem = 86278362 |
||
| DrugBank = DB12839 |
| DrugBank = DB12839 |
||
Line 63: | Line 63: | ||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
{{Other alimentary tract and metabolism products}} |
|||
[[Category:Drugs acting on the gastrointestinal system and metabolism]] |
[[Category:Drugs acting on the gastrointestinal system and metabolism]] |
||
[[Category:Recombinant proteins]] |
[[Category:Recombinant proteins]] |
||
{{ |
{{gastrointestinal-drug-stub}} |
Revision as of 19:24, 24 December 2019
Clinical data | |
---|---|
Trade names | Palynziq |
Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
Pegvaliase (trade name Palynziq) is a medication for the treatment of the genetic disease phenylketonuria.[2] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[3]
It was approved by the Food and Drug Administration for use in the United States in 2018.[2]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b "FDA approves a new treatment for PKU, a rare and serious genetic disease". Food and Drug Administration. May 24, 2018.
- ^ "Palynziq". BioMarin Pharmaceutica.